Mansfield C, Sutphin J, Boeri M. Assessing the impact of excluded attributes on choice in a discrete choice experiment using a follow-up question. Health Econ. 2020 Oct;29(10):1307-15. doi: 10.1002/hec.4124
Sheer R, Schwab P, Essex MN, Cappelleri JC, Reiners A, Bobula J, Pasquale MK. Factors related to the use of topical vs. oral NSAIDs for sprains, strains, and contusions in a senior population: a retrospective analysis of administrative claims data. Drugs Aging. 2018 Oct;35(10):937-50. doi: 10.1007/s40266-018-0585-8
Heidenreich S, Watson V, Ryan M, Phimister E. Decision heuristic or preference? Attribute non-attendance in discrete choice problems. Health Econ. 2018 Jan;27(1):157-71. doi: 10.1002/hec.3524
Tsuchiya A, Watson V. Re-thinking “the different perspectives that can be used when eliciting preferences in health". Health Econ. 2017 Dec;26(12):e103-7. doi: 10.1002/hec.3480
Krucien N, Watson V, Ryan M. Is best-worst scaling suitable for health state valuation? A comparison with discrete choice experiments. Health Econ. 2017 Dec;26(12):e1-e16. doi: 10.1002/hec.3459
Watson V, Becker F, de Bekker-Grob E. Discrete choice experiment response rates: a meta-analysis. Health Econ. 2017 Jun;26(6):810-7. doi: 10.1002/hec.3354
Gascon M, Cirach M, Martinez D, Dadvand P, Valentin A, Plasencia A, Nieuwenhuijsen MJ. Normalized difference vegetation index (NDVI) as a marker of surrounding greenness in epidemiological studies: the case of Barcelona city. Urban For Urban Green. 2016 Sep;19:88-94. doi: 10.1016/j.ufug.2016.07.001
Schwab P, Louder A, Li Y, Mallick R, Bays H. Cholesterol treatment patterns and cardiovascular clinical outcomes associated with colesevelam HCl and ezetimibe. Drugs Aging. 2014 Sep;31(9):683-94. doi: 10.1007/s40266-014-0200-6
Zarkin GA, Cowell AJ, Hicks KA, Mills MJ, Belenko S, Dunlap LJ, Houser KA, Keyes V. Benefits and costs of substance abuse treatment programs for state prison inmates: results from a lifetime simulation model. Health Econ. 2012 Jun;21(6):633-52.
Lukert B, Satram-Hoang S, Wade S, Anthony MS, Gao G, Downs R. Physician differences in managing postmenopausal osteoporosis: results from the POSSIBLE US™ treatment registry study. Drugs Aging. 2011 Sep 1;28(9):713-27.
Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med. 2011 Feb 14;171(3):218-25.
Ryan M, Watson V. Comparing welfare estimates from payment card contingent valuation and discrete choice experiments. Health Econ. 2009 Apr;18(4):389-401. doi: 10.1002/hec.1364
Ryan M, Watson V, Entwistle V. Rationalising the 'irrational': a think aloud study of discrete choice experiment responses. Health Econ. 2009 Mar;18(3):321-36. doi: 10.1002/hec.1369
Simpkins J, Divine G, Wang M, Holmboe E, Pladevall-Vila M, Williams LK. Improving asthma care through recertification: a cluster randomized trial. Arch Intern Med. 2007 Nov 12;167(20):2240-8.
Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med. 2007 Feb 12;167(3):290-5.
Zarkin GA, Dunlap LJ, Hicks KA, Mamo D. Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ. 2005 Nov 1;14(11):1133-50.
Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley DJ, Mangel AW. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med. 2001 Jul 23;161(14):1733-40.
Bollini P, Garcia Rodriguez LA, Perez GS, Walker AM. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med. 1992 Jun 1;152(6):1289-95.
Jick H, Porter J, Morrison AS, Rothman KJ. Lung cancer in young women. Arch Intern Med. 1979 Jul 1;139(7):745-6.